 Biotech M&A Strategies: Deal assessments, trends and future prospects
M&A activity in the pharma industry continues to gain momentum as a growing number of companies seek to replenish drug pipelin
Table of contents List of tables / figures |
2008 |
3.835,00$ |
The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
The dermatology market remains highly competitive, with developers ranging from Big Pharma to biotechnology and specialty pharmace
Table of contents List of tables / figures |
2008 |
3.835,00$ |
Women's Reproductive Disorders Therapeutics 2008-2018
Overview of the women’s reproductive therapies market
/ Key industrial players in the global women’s reproductive therapies marke
Table of contents List of tables / figuresExtract |
2008 |
3.000,00$ |
Amgen Inc.: PharmaVitae Profile
This analysis examines the historical and forecast performance for Amgen in the ethical pharmaceutical sector. The profile encompa
Table of contents List of tables / figures |
2008 |
5.700,00$ |
AstraZeneca plc: PharmaVitae Profile
This analysis examines the historical and forecast performance for AstraZeneca in the ethical pharmaceutical sector. The profile e
Table of contents List of tables / figures |
2008 |
5.700,00$ |
Bayer Schering Pharma AG: PharmaVitae Profile
This analysis examines the historical and forecast performance for Bayer Schering Pharma in the ethical pharma sector. The profile
Table of contents List of tables / figures |
2008 |
5.700,00$ |
Bristol-Myers Squibb Co.: PharmaVitae Profile
This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompass
Table of contents List of tables / figures |
2008 |
5.700,00$ |
Commercial and Pipeline Insight: Fibromyalgia - Approvals legitimize condition and expose underserved patient population
Analysis of clinical trial design and treatment guidelines in fibromyalgia. / / Fibromyalgia market sizing assessment with detail
Table of contents List of tables / figures |
2008 |
15.200,00$ |
Commercial and Pipeline Insight: Vaccines for Adults and the Elderly - New blockbuster opportunities ahead
Assessment of pneumococcal and zoster disease incidence, in-depth analysis of existing vaccines and key pipeline compounds / / R
Table of contents List of tables / figures |
2008 |
15.200,00$ |
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming patent expiries limit market growth
Analysis of the performance of each of the cytotoxic therapy cancer brands in the seven major markets, forecast to 2017
/
/ Ana
Table of contents List of tables / figures |
2008 |
15.200,00$ |
Commercial Insight: Targeted Therapy Cancer Brands - High growth market will see eight new blockbusters by 2017
Forecast sales of every marketed targeted therapy cancer brand in each of the seven major markets over the period 2007 to 2017
/
Table of contents List of tables / figures |
2008 |
15.200,00$ |
Financial Deals Industry Tracker: Pharmaceuticals and Healthcare (analysis of monthly deal activity, along with the trend for the last six months for merger and acquisition (M&A), private equity, venture financing, private placement, initial public offeri
Insights into deal activity across M&A, private equity, private placement, IPO, and secondary offering deals / In-depth analysis
Table of contents List of tables / figures |
2008 |
495,00$ |
Generic Series: Optimizing Brand Lifecycle Management Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition
Review of key reasons why lifecycle management is important now / / Analysis of key considerations Pharma need to take care of wh
Table of contents List of tables / figures |
2008 |
7.600,00$ |
Johnson & Johnson: PharmaVitae Profile
This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompass
Table of contents List of tables / figures |
2008 |
5.700,00$ |
MarketWatch: Biotechnology
Datamonitor's Biotechnology MarketWatch is a one-stop news shop for time-pressed executives. It provides monthly insight into the
Table of contents List of tables / figures |
2008 |
200,00$ |
MarketWatch: Cancer
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives. It provides monthly insight into the key eve
Table of contents List of tables / figures |
2008 |
200,00$ |
MarketWatch: CNS
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives. It provides monthly insight into the key events
Table of contents List of tables / figures |
2008 |
200,00$ |
MarketWatch: Health Round-up
Datamonitor's MarketWatch Health Round-up is a one-stop news shop for time-pressed executives. It provides monthly insight into th
Table of contents List of tables / figures |
2008 |
400,00$ |
Novo Nordisk A/S: PharmaVitae Profile
This analysis examines the historical and forecast performance for Novo Nordisk in the ethical pharmaceutical sector. The profile
Table of contents List of tables / figures |
2008 |
5.700,00$ |
PharmaVitae: Company Comparator Tool
The Comparator Tool builds from the PharmaVitae profiles of the 50 leading pharma companies. Updated monthly, the tool allows you
Table of contents List of tables / figures |
2008 |
45.600,00$ |
Pipeline Insight: Insulin antidiabetics - Return to injections alternative delivery methods fall by the wayside
Comprehensive analysis of the current insulin antidiabetic pipeline detailing the broad range of developmental classes. / / A det
Table of contents List of tables / figures |
2008 |
11.400,00$ |
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
Overview of the Rx-to-OTC strategy, analyzing why, when, where, what and how to implement such a switch strategy / / Identificati
List of tables / figures |
2008 |
5.700,00$ |
Schering-Plough Corporation: PharmaVitae Profile
This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encom
Table of contents List of tables / figures |
2008 |
5.700,00$ |
Stakeholder Insight: Asthma - Over-prescribing is common in intermittent and mild forms of asthma
Patient segmentation with regards to disease severity, asthma phenotypes, co-morbidities and exacerbations / / Treatment choice s
Table of contents List of tables / figures |
2008 |
15.200,00$ |
Stakeholder Opinions: Diagnostics in Neurology - Predictive biomarkers expand drug revenues
Neurological conditions covered: Alzheimer's disease, Parkinson's disease, MS, epilepsy, migraine, insomnia, Huntington's disease
Table of contents List of tables / figures |
2008 |
3.800,00$ |
